Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, Bioscan to Co-Market Imaging Instruments, Software

NEW YORK (GenomeWeb News) – Definiens and Bioscan have signed an agreement to co-market Bioscan’s instruments for noninvasive in vivo animal imaging with Definiens’ image analysis software, the companies said today.
Bioscan, based in Morristown, NJ, and Definiens, based in Munich, Germany, said they have agreed to “conduct cooperative marketing activities and host joint workshops and events” that will offer customers integrated training and implementation programs.
The firms said they will “continue to explore further opportunities for cooperation,” which could include the co-development of user interfaces to incorporate Definiens’ software into Bioscan’s hardware.
Existing Bioscan customers will also receive “introductory offers” for Definiens applications, the partners said.
Bioscan offers the NanoSPECT/CT and NanoPET/CT in vivo animal imaging systems, which analyze molecular function at the nanoliter scale.
Definiens’ Cognition Network Technology software is used for analyzing image data from a range of platforms, including cell and tissue-based assays and in vivo imaging systems.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.